Search
for
Sort by
Research 481–510 of 1000+
- Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia
- Synthesis, Characterization and Evaluation of 5α, 6β-Dihalo Androsterone Derivatives as 5α-Reductase Inhibitors
- Comparative clinical assessment of 5% minoxidil topical application with supplemental intradermal meso-solution administration for the management of androgenetic alopecia in men
- Patient Satisfaction and Quality of Life Among Adult Women with Androgenetic Alopecia Using 5% Topical Minoxidil.
- 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia (vol 35, pg e243, 2021)
- The “NOMINAL” trial: Clinical efficacy, cosmetic acceptability, and local tolerability of topical 5% minoxidil lotion without propylene glycol: A 6-month, multicentre, real-life, prospective, assessor-blinded study in 196 subjects with hair loss.
- Methylated CpG dinucleotides in 5-α reductase 2 gene might explain the finasteride-resistance in BPE patients
- Does microneedling with 5% minoxidil offer added advantage for treatment of androgenetic alopecia in comparison to use of topical 5% minoxidil alone?
- Microneedling and Platelet-Rich Plasma versus Microneedling and 5% Topical Minoxidil Therapy in Male Pattern Hair Loss.
- Microneedling and Platelet-Rich Plasma versus Microneedling and 5% Topical Minoxidil Therapy in Male Pattern Hair Loss.
- A Review on Finasteride: A 5-Alpha Reductase Inhibitors, its Mechanism, Facts and Benefits
- Change in Hair Growth-related Gene Expression Profile in Human Isolated Hair Follicles Induced by 5-alpha Reductase Inhibitors, Dutasteride and Finasteride, in the Presence of Testosterone
- A comparative study of efficacy and safety of 5% topical minoxidil with platelet rich plasma versus platelet rich plasma as a monotherapy in male patients with androgenetic alopecia
- Effects of 5-?±-Reductase Inhibitor (Finasteride) on Per Operative Blood Loss in Patients with BPH undergoing TURP
- 102 Methylation of CpG islands in promoter of type 2 5-α reductase and implications of finasteride resistance for BPH therapy
- Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL)
- Sponsored Lecture 3 : Updates on 5 alpha-rers(5ARIs) for the treatment of male pattern hair loss(MPHL)
- Faculty Opinions recommendation of A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
- Trichoscan: results using a 5% minoxidil topical solution in men with androgenetic alopecia
- Particulate matter 2.5 damages skin cells by inducing oxidative stress, subcellular organelle dysfunction, and apoptosis
- Conditional Gene Expression in the Epidermis of Transgenic Mice Using the Tetracycline-Regulated Transactivators tTA and rTA Linked to the Keratin 5 Promoter
- Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP−Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor
- Steroid 5α-reductases and 3α-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism
- Critical Developmental Periods for Effects on Male Rat Genitalia Induced by Finasteride, a 5α-Reductase Inhibitor
- Evidence of Heterogeneity and Quantitative Differences of the Type 1 5α-Reductase Expression in Cultured Human Skin Cells – Evidence of its Presence in Melanocytes
- Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
- Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation
- Human Osteoblast-Like Cells Express Predominantly Steroid 5α-Reductase Type 1
- Efficient In Vivo Targeting of Epidermal Stem Cells by Early Gestational Intraamniotic Injection of Lentiviral Vector Driven by the Keratin 5 Promoter
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases